Send to

Choose Destination
Int J Biochem Cell Biol. 2009 Apr;41(4):729-32. doi: 10.1016/j.biocel.2008.04.028. Epub 2008 Aug 13.

CCL2 DNA vaccine to treat renal disease.

Author information

Centre for Kidney Research, Children's Hospital at Westmead, Westmead, New South Wales, Australia.


CCL2 DNA vaccines are directed against the host chemoattractant molecule CCL2 (MCP-1), a key chemokine in recruiting macrophages to sites of inflammation. Macrophages recruited by CCL2 lead to progressive renal injury. In rat models of disease unmodified CCL2 DNA vaccine in combination with a CCL5 (RANTES) DNA vaccine can protect against chronic renal disease. The mechanism of protection involves the induction of auto-antibodies to the CCL2. Introduction of the adjuvant p-tet into the DNA structure of the CCL2 vaccine leads to enhanced potency with the induction of specific Th1 cellular immunity. The strategies outlined here demonstrate a model for developing potent vaccines against highly restricted self targets.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center